Views & Analysis | Perspectives on pharma industry issues

Patients

Innovation can transform NHS care, but scaling is the missin...

Innovation is already improving care across the NHS, but we are not yet consistently delivering at scale for the benefit of patients

R&D

A physiotherapist assists an ALS patient

Treating mechanisms, not symptoms: ALS R&D today

The ALS clinical trial landscape is characterised by a significant number of active trials and sponsors, including MediciNova's Ph3 with MN-166.

R&D

Why storage resilience will protect the future of CAR-T

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage.

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

R&D

Changing Faces: Pharma and biotech hires, June & July 2026

In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.

Views & Analysis

UCB’s James Musick on embracing digital therapeutics

Digital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it.

Views & Analysis

Supporting the next generation of digital pharmacies

This year marks the 20th anniversary of the UK’s first internet pharmacy and the sector has steadily increased, particularly after the 2005 rule change that meant they could start filling N

Views & Analysis

How to conduct a patient centric clinical study

Listen and support: How to conduct a patient-centric clinica...

Clinical trial sponsors understand the value of patient-centric studies, but success relies on a time-consuming paradigm shift and progress is slow.

Sales & Marketing

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs